论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
免疫疗法联合放射疗法治疗肉瘤:是否存在协同作用的潜力?
Authors Wang J , Ge H , Tian Z
Received 1 March 2023
Accepted for publication 25 May 2023
Published 7 June 2023 Volume 2023:16 Pages 385—397
DOI https://doi.org/10.2147/OTT.S410693
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Arseniy Yuzhalin
Abstract: Soft tissue sarcoma (STS) is a highly heterogeneous malignant tumor derived from mesenchymal tissue. Advanced STS has a poor response to the current anti-cancer therapeutic options, with a median overall survival of less than two years. Thus, new and more effective treatment methods for STS are needed. Increasing evidence has shown that immunotherapy and radiotherapy have synergistic therapeutic effects against malignant tumors. In addition, immunoradiotherapy has yielded positive results in clinical trials for various cancers. In this review, we discuss the synergistic mechanism of immunoradiotherapy in cancer treatment and the application of this combined regimen for the treatment of several cancers. In addition, we summarize the existing evidence on the use of immunoradiotherapy for the treatment of STS and the relevant clinical trials that are currently ongoing. Furthermore, we identify challenges in the use of immunoradiotherapy for the treatment of sarcomas and propose methods and precautions for overcoming these challenges. Lastly, we propose clinical research strategies and future research directions to help in the research and treatment of STS.
Keywords: PD-1 inhibitor, PD-L1 inhibitor, immune checkpoint inhibitor, radiotherapy, sarcoma, immunoradiotherapy